MannKind Assigned Patent

ALEXANDRIA, Va., Jan. 19 -- MannKind, Valencia, Calif., has been assigned a patent (8,354,380) developed by Liping Liu, Manassas, Va., Adrian Bot, Valencia, Calif., and David C. Diamond, West Hills, Calif., for NY-ESO-1 peptide analogs.

The abstract of the patent published by the U.S. Patent and Trademark Office states: "Some embodiments relate to analogs of peptides corresponding to class I MHC-restricted T cell epitopes and methods for their generation. These analogs can contain amino acid substitutions at residues that directly interact with MHC molecules, and can confer improved, modified or useful immunologic properties. Additionally classes of analogs, in which the various substitutions comprise the non-standard residues norleucine and/or norvaline, are disclosed."

The patent application was filed on June 17, 2005 (11/155,929). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,354,380&OS=8,354,380&RS=8,354,380

Written by Satyaban Rath; edited by Hemanta Panigrahi.

***

http://www.equities.com/news/headline-story?dt=2013-01-19&val=945063&cat=material